Related Experiment Video
Updated: Feb 1, 2026

Detection of Alternative Splicing During Epithelial-Mesenchymal Transition
Published on: October 9, 2014
Alternative Acts: Oncogenic Splicing of Steroidogenic Enzymes in Prostate Cancer
1Geriatric Research, Education and Clinical Center, VA Puget Sound Health Care System, Seattle, Washington. emostagh@fredhutch.org.
Abstract:
Castration-resistant prostate cancer is characterized by loss of the androgen inactivation enzyme HSD17B2, emphasizing the importance of intratumoral androgens in tumor progression. Inactive isoforms generated by alternative splicing destabilize the wild-type enzyme, adding steroidogenesis to other prostate cancer drivers that undergo oncogenic splicing, highlighting aberrant splicing as a therapeutic target.See related article by Gao et al., p. 1291.
Insights
Castration-resistant prostate cancer involves loss of the HSD17B2 enzyme, crucial for androgen inactivation. Aberrant splicing creates inactive enzyme forms, driving tumor growth and offering a new therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Castration-resistant prostate cancer (CRPC) progression is linked to intratumoral androgens.
- The androgen inactivation enzyme, HSD17B2, is often lost in CRPC.
- Androgen signaling remains a key driver in advanced prostate cancer.
Purpose of the Study:
- To investigate the role of HSD17B2 and alternative splicing in CRPC.
- To explore aberrant splicing as a potential therapeutic strategy for prostate cancer.
Main Methods:
- Analysis of HSD17B2 expression and alternative splicing in prostate cancer tissues.
- Investigating the functional impact of HSD17B2 isoforms on enzyme activity and androgen levels.
Main Results:
- Loss of functional HSD17B2 is a hallmark of CRPC.
- Alternative splicing generates inactive HSD17B2 isoforms that destabilize the wild-type enzyme.
- Aberrant splicing contributes to elevated intratumoral androgen levels, promoting tumor progression.
Conclusions:
- Intratumoral androgen production, driven by aberrant splicing of HSD17B2, is critical for CRPC.
- Targeting aberrant splicing represents a promising therapeutic avenue for castration-resistant prostate cancer.
Related Concept Videos
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Alternative RNA Splicing
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
RNA Splicing
Enzymes
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
Forces Acting on Chromosomes
Microtubules and motor proteins exert two types of forces on...

